Galleri Multi-Cancer Early Detection
A blood test that screens for 50+ cancers - controversial, expensive, and the most-debated longevity diagnostic of 2026.
A blood test screening for 50+ cancers - the most-debated longevity diagnostic of 2026.
Galleri (made by GRAIL, an Illumina spinout) detects circulating tumor DNA across 50+ cancer types from a single blood draw, and predicts the tissue of origin if cancer signal is found. It's the closest thing to a "screening for everything" blood test that exists.
The data behind it is real but nuanced: in published studies it has a high specificity (low false-positive rate, ~99.5%), moderate sensitivity (catches roughly 50% of stage-I cancers, higher at later stages), and the tissue-of-origin prediction is right ~88% of the time. For a screening test, that's genuinely good. For a definitive diagnostic, that's incomplete.
Who should consider it: people over 50, anyone with significant family cancer history, and longevity-focused buyers with the budget who want an additional screening layer beyond colonoscopy/mammogram/etc. Who shouldn't: anyone prone to over-treating uncertain findings (a positive Galleri triggers a follow-up imaging cascade that's itself non-trivial).
Buyers over 50, those with family cancer history, longevity-focused spenders adding a screening layer to standard surveillance.
You're under 40 with no family history (false-positive math is unfavorable), or you can't afford the follow-up imaging if it triggers.
Specifications
Most often compared with
Where this fits
Galleri Multi-Cancer Early Detection Test cross-shops across several editorial surfaces - the full brand catalog, the buyer-intent tags this item carries, the price band it qualifies for, and any execution playbook that uses it.
Galleri Multi-Cancer Early Detection Test - buyer FAQ
How accurate is Galleri actually?
Specificity ~99.5% (very low false-positive rate) and sensitivity ~50% for Stage I cancers (higher at later stages). The tissue-of-origin prediction is right ~88% of the time when a signal is found. Translation: if Galleri says you don't have detectable cancer, you very likely don't. If it says you might, follow-up imaging is needed to confirm or rule out. Strong specificity, moderate sensitivity.
Does Galleri replace colonoscopy / mammogram / standard screening?
No - it's additive, not a replacement. Standard age-appropriate screening (colonoscopy, mammogram, PSA, low-dose CT for smokers) is still recommended. Galleri adds a screening layer for cancers that don't have routine screening tests (pancreas, ovary, liver, etc). Many longevity-pro buyers run Galleri annually alongside age-appropriate standard surveillance.
What happens if Galleri detects a signal?
You're referred for diagnostic imaging (typically CT, MRI, or PET scan depending on tissue-of-origin prediction) to confirm or rule out. The follow-up imaging cascade is itself non-trivial - it can cost $500-3,000 out of pocket if insurance doesn't cover, plus the anxiety window before confirmation. Buyers prone to over-treating uncertain findings should weigh this carefully before testing.
Is Galleri covered by insurance?
Generally no - GRAIL is working through FDA approval and Medicare coverage as of 2026, but most commercial insurance does not currently cover the $949 list price. HSA/FSA reimbursement varies by plan administrator. Some Medicare Advantage plans cover it through pilot programs. Verify your specific coverage before ordering.
Who should NOT get Galleri?
Under 40 with no family history (false-positive math doesn't favor screening at that population age - the follow-up imaging cascade catches more incidentals than meaningful cancers). Anyone who would experience disabling anxiety from an uncertain positive result. Anyone without budget for the $500-3,000 follow-up imaging if a signal triggers. Best use case: 50+ or with strong family history.